This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Yet despite these and other claims , including those spreading on social media , there is as of yet no substantiated clinical data supporting either the prophylactic or therapeutic use of cannabis products in the treatment of COVID-19.
The Cannigma has always taken a data-informed approach to content creation – though up until recently we’ve been primarily leaning on the existing peer-reviewed literature to guide our content. We need more data – human data – on specific applications for the plant – symptoms, use cases, conditions and patient types.
Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. Anonymized data also helps scientists better understand the cannabis plant and what products and chemical profiles are most effective for treating different conditions and symptoms.
A medical patient could end up in jail for possessing even small amounts of marijuana. Currently, with t he required certificate from a certified medical practitioner due to a qualifying condition, medical marijuana possession for patients is allowed in South Dakota. Patients cannot cultivate without explicit authorization.
Patients who suffer from epilepsy , which affects some 3.4 Pharmaceutical CBD is currently a restricted prescription medication, and insurance coverage is often limited to only those patients with the specific approved indications. Researchers Analyzed Survey Results from 280 Epilepsy Patients.
New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. Media Contact: Will Johnson. 646) 421-9523. 201-465-8019.
The new website includes dropdown menus for information about CROO Media , Research and Data , Legal and Enforcement , About , and Agencies. The Media information includes Press Releases, Newsletters, Reports and Public Presentations, and Upcoming Dates. For more Illinois cannabis industry news, visit here.
Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. (CSE: Source: Data Bridge.
A high-quality patient experience is paramount in any healthcare setting. Satisfied patients are more likely to trust their healthcare providers. It encourages patients to ask questions, provide accurate information, and participate in shared decision-making, leading to better treatment adherence and overall care quality.
A panel of Commonwealth Court judges has ordered the Wolf administration to reveal how many medical marijuana patients have received approval from a doctor to use cannabis for opioid addiction treatment. The newsroom specifically requested aggregate data — information that would not identify individual patients.
The lab was born to fulfill an unmatched need in the industry to deliver a reliable, scientifically based standard methodology to allow patients to control their individual dose and overall predictability of a product’s intended therapeutic effects. “We Media Contact: Shawna Hassett, shassett@duffyshanley.com.
Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.
Understanding Gen Z Gen Z has been spotlighted in the media recently for a variety of reasons, one of which is that they are the largest consumers of media across any generation. By knowing what Gen Z values about cannabis, we can better provide for upcoming generations to ensure everyone is having their needs met.
is expected to release its Keytruda data from two Phase III trials this year. s active testing of Keytruda in a single-agent setting and in combination with chemotherapy of physician’s choice, may ultimately allow Keytruda to be used in broader patient populations. To gain access to our latest press releases: GlobalData Media Centre.
Today, both patient experience and modern scientific research support claims of medical marijuana’s effectiveness for pain management. Questions included any changes in personal levels of opioid use when marijuana was also used, and the reasons why patients were substituting marijuana for prescription pain medications.
A Windsor, Ontario-based company Audacia Bioscience is especially focussed on three patented technologies that deliver consumer and patient insights to the industry to close the knowledge gaps in the supply chain. Cognizance VCT enables the generation of cost-effective quality data with ethical consent, on par with academic studies.
According to the amendment to the law on addictive substances and drugs, which came into force on January 1, doctors will now only prescribe medical marijuana to their patients electronically. Almost 200 doctors throughout the Czech Republic are currently prescribing therapeutic cannabis to some of their patients. Source: CTK.
The Board will further serve as a resource for media, other medical associates and general audiences interested in the science behind psychedelic wellness and treatments. Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.
Believe it or not, many cancer patients in Miami have been clearing the shelves to not only relieve cancer pain , but also for the hope that RSO can help them with the cancer itself. This hope comes from many individuals posting their stories (true or not) on social media. What Makes RSO Special?
From medical patients to MSOs, News Joint Consulting connects clients to cannabis insiders across the industry, including academics, municipalities, politicians, associations, event planners, conference organizers, vendors, new business owners, cultivators, breeders, brands, influencers, and more.
Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. COMP360 psilocybin therapy has now been given to 233 patients, exceeding 216 target. On track to report top-line data by end of 2021. million, or $0.79 million, or $2.61
Our initial data suggest that some C. Note: Study extracts were applied via media. CannaMD will continue to keep patients updated as more information becomes available. But what does marijuana have to do with ACE2? Our results lay a foundation for further in-depth analysis of the effects of C. Find a Medical Marijuana Doctor.
This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Of the 22 patients, 19 experienced adverse events after ingesting delta-8 THC-containing food products (e.g.,
Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, “Addiction”, which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. Ehave, Inc. Forward-Looking Statement Disclaimer.
Data from Marijuana Business Daily’s 2021 Annual Marijuana Business Factbook puts the growth potential of the cannabis industry over the next several years into perspective. According to the data in the 2021 Annual Marijuana Business Factbook , U.S. Cannabis Sales Growth. cannabis sales will climb to $48.4 View original article.
16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.
The medical use of certain psychedelic drugs and substances remain illegal under Canadian federal law unless discretionary exemptions are granted under the CDSA, while a limited number of other drugs and substances may be prescribed by a health care practitioner to patients under their care. SOURCE Horizons ETFs Management ( Canada ) Inc.
The full media report dated 30 August 2019 can be found at. According to a media report , the German government took almost 13.3 These data are based on an extrapolation of the top pharmacist association. At the end of 2020, cannabis from German cultivation should be available for patients. ( Leafly.de reported. ).
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. The cannabis research problem. There’s another problem: science communication and literacy.
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.fda.gov/media/131878/download. Epilepsy Behav.
The letters were sent “in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.” Specifically, the agency fears that.
. “By acquiring traditional healthcare assets and subsequently layering in alternative medicines and psychedelic therapies as regulations develop, Levitee will have direct and immediate access to a much broader patient population. Levitee Media Contact. media@leviteelabs.com. The CSE (operated by CNSX Markets Inc.)
Deal size aside, we wanted to share what we look at on the data side when a public company or MSO announces a deal. Today, Curaleaf LLC is one of four licensed growers in Connecticut and operates a 60,000 square foot cultivation facility in Simsbury that provides cannabis products to over 40,000 patients throughout the state.
Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols. Lobo brings a highly experienced and specialized team of technology experts in the fields of genetics, diagnostics, data and analytics, as well as a fully operational 5,000 sq. Vancouver, British Columbia–(Newsfile Corp.
With the immense popularity of Kaviar spawning in such a short time, the team invested heavily in marketing at industry events, interacting with customers directly at dispensaries, and cultivating an engaging following on social media. To qualify and receive a medical patient card at a discounted rate, visit here.
As we move forward into 2024 and beyond, the sector offers diverse paths beyond direct patient care. The growth stems from rising healthcare demand, facility expansion, and the imperative for efficient administration to maintain quality patient care. Adverse drug events (ADEs) affect approximately 7 per 100 hospitalized patients.
“Oravax’s studies of its VLP vaccine for COVID-19 should be of particular interest to MyMD shareholders given our own upcoming Phase 2 clinical trial of MYMD-1 to treat immune mediated depression and cytokine elevation in COVID-19 patients. Media Contact: Will Johnson. About Oravax Medical. Investor Contact: Robert Schatz.
There have been various individual studies of the condition, but the Ehave study could be the largest patient study to date. EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Media Inquiries: Gabe Rodriguez. Forward-Looking Statement Disclaimer. Contact: Ehave Inc.
After months of development, my partner and I built and successfully launched the beta for our cannabis data-analytics software, Jade Insights. It’s a software platform that helps cannabis businesses augment their process by providing insights for data-backed decision-making. ” JOHN KAGIA. ” OPHELIA CHONG.
Despite surging sales and patient numbers, Oklahoma ended 2020 with 181 fewer retail licenses than it did in 2019 – even after issuing 565 new permits throughout 2020, according to Cannabiz Media, a Connecticut-based cannabis license database and marketing platform. The entire U.S. licenses per 1,000 people.
London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE. ” About COMPASS Pathways.
Former President Bill Clinton has apparently been hearing a lot about the therapeutic potential of CBD products for pain management lately, and, according to a now-deleted media report, said at a recent conference appearance that broad interest in the topic should spur regulators to develop standards for the cannabinoid. Ganjapreneur report.
While COVID-19 can be deadly, the World Health Organization (WHO) stresses that most patients experience mild cases and/or survive: Most people who get COVID-19 have mild or moderate symptoms and can recover thanks to supportive care. Our initial data suggest that some C. Note: Study extracts were applied via media.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content